The development of antisense oligonucleotide (ASO) therapies for SOD1-mutation-related ALS has progressed through various preclinical and clinical trials, culminating in the Food and Drug Administration (FDA)’s approval of tofersen in April 2023 [8]. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.